Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

• Published in: Cancer Vol. 68; no. 8; pp. 1696 - 1698
• Main Authors: Oster, Martin W., Schilsky, Richard L., Faraggi, David, Korzun, Ann H., Perry, Michael, Moore, Ann, Kalra, Jagmohan, Wood, William C., Craig Henderson, I.
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 15.10.1991
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Cisplatin - administration & dosage; Cytarabine - administration & dosage; Drug Administration Schedule; Drug Evaluation; Female; Humans; Middle Aged; Prospective Studies; Survival Rate
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19911015)68:8<1696::AID-CNCR2820680807>3.0.CO;2-B

Forty‐four women with advanced breast cancer participated in a prospective clinical trial to evaluate the efficacy and toxicity of a regimen consisting of cytosine arabinoside and cisplatin. All patients had previously received chemotherapy. Three patients (7%) responded to therapy with response durations of 153, 160, and 441 days. The median time to disease progression and median survival time in all 44 patients were 2.3 and 5 months, respectively. This regimen had significant toxicity, with most patients experiencing severe or life‐threatening hematologic, renal, or infectious complications. This regimen cannot be recommended for previously treated patients with advanced breast cancer.